Quarterly Activities/Appendix 4C Cash Flow Report

Resonance Health Ltd has released its Quarterly Activities & Cashflow Report for the quarter ending September 30, 2025. Key highlights include $3.1M in customer receipts and a positive net cashflow of $0.1M. The company saw receipts of $13.75M over the last 12 months, with positive net cash flow of $1.43M. Operations saw progress across all business segments, with the major-pharma clinical trial services agreement advancing and new contracts awarded in the SaMD business. Cash at the end of the quarter was $3.0M, with a net cash position of $0.2M after accounting for debt.

Resonance Health made significant strides in its Resonance Clinical, SaMD, and TrialsWest divisions during the quarter. The major-pharma clinical trial saw key milestones achieved, while new contracts were secured in the SaMD business. The TrialsWest expansion continued with the opening of a new site, further supporting revenue growth.

Looking ahead, the company is exploring opportunities in China's healthcare market and continues to focus on growth across all business segments. CEO Andrew Harrison expressed optimism over the business's trajectory, citing a strong sales pipeline and growth potential in new markets. Investors are invited to ask any questions they may have about the announcement. Visit our website for more information.